Ryu Tiger, Y. K., Jain, S., Barta, S. K., Tolu, S., Estrella, B., Sawas, A., Lue, J. K., Francescone, M. M., Pro, B., & Amengual, J. E. (2024). Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leukemia & Lymphoma, 65(6), 736–745. https://doi.org/10.1080/10428194.2024.2329996

Shih, B. B., Ma, C., Cortes, J. R., Reglero, C., Miller, H., Quinn, S. A., Albero, R., Laurent, A. P., Mackey, A., Ferrando, A. A., Geskin, L., & Palomero, T. (2024). Romidepsin and Afatinib Abrogate Jak–Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 144(7), 1579-1589.e8. https://doi.org/10.1016/j.jid.2023.12.010

Ruan, J., Zain, J., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., Petrich, A. M., & Pro, B. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances, 7(19), 5771–5779. https://doi.org/10.1182/bloodadvances.2023009767